Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to Buy Monte Rosa Therapeutics (Monte Rosa Therapeutics) Stock

Buy Monte Rosa Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Monte Rosa Therapeutics is a biotechnology business based in the US. Monte Rosa Therapeutics shares (GLUE) are listed on the NASDAQ and all prices are listed in US Dollars. Monte Rosa Therapeutics employs 147 staff and has a trailing 12-month revenue of around $181.5 million.

Our top picks for where to buy Monte Rosa Therapeutics stock

Top pick for stock bonuses

  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options with no options contract fees
  • Get up to $1,000 in stock when you open and fund a new account within 45 days
  • Access to a financial planner
Probability of Member receiving $1,000 is a probability of 0.026%; If you don’t make a selection in 45 days, you’ll no longer qualify for the promo. Customer must fund their account with a minimum of $50.00 to qualify. Probability percentage is subject to decrease.

Terms and conditions apply*. For 401k rollovers, existing SoFi IRA members must complete 401k rollovers via this link For SoFi members without a SoFi IRA, a SoFi IRA must first be opened, and 401k rollover must be completed utilizing Capitalize via this link. SoFi and Capitalize will charge no additional fees to process a 401(k) rollover to a SoFi IRA. SoFi is not liable for any costs incurred from the existing 401k provider for rollover. Please check with your 401k provider for any fees or costs associated with the rollover. For IRA contributions, only deposits made via ACH and cash transfer from SoFi Bank accounts are eligible for the match. Click here for the 1% Match terms and conditions.

Up to 2% match

  • Trade stocks, ETFs, options, futures and bonds all in one place
  • $0 commissions on stocks, ETFs and equity options, with low contract fees
  • Deposit or transfer $10,000+ to earn a 2% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&C apply.

Top pick for simple, worldwide trading

  • Trade stocks, ETFs, mutual funds, options and cryptocurrency
  • Worldwide stock and options trading
  • Commission-free stocks, ETFs and no transaction fee mutual funds
  • Invest with as little as $1

How to buy Monte Rosa Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – GLUE. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Monte Rosa Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
12 of 12 results
Finder Score Available asset types Stock trade fee Minimum deposit Cash sweep APY bullet point infobox
Finder score
Stocks, Bonds, Options, Mutual funds, ETFs, CDs
$0.01
$250
2.83%
Leverage powerful trading tools and low margin rates to trade stocks, options, ETFs, mutual funds and bonds.
Finder score
Stocks, Options, ETFs, Cryptocurrency, Futures, Event contracts, High-yield cash account
$0
$0
3.50%
Get a free stock when you successfully sign up and link your bank account. T&Cs apply.
Trade stocks, options, crypto and more, with advanced trading tools, fractional shares and exclusive perks for Gold members.
Finder score
Stocks, Bonds, Options, ETFs, Cryptocurrency, Investments, Retirement, Treasury Bills, High-yield cash account
$0
$0
3.6%
Get up to $10,000 and transfer fees covered when you move your portfolio to Public. T&Cs apply.
Build a diversified portfolio of stocks, bonds, options, ETFs and crypto, with a high-yield cash account and options contract rebates.
SoFi Wealth Management logo
Finder score
Finder score
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.01%
Get up to $1,000 in stock when you open and fund a new account. T&Cs apply.
Trade stocks, ETFs, and options with zero commissions, invest in IPOs or automate your portfolio, with exclusive perks available through SoFi Plus.
Webull logo
Finder score
Finder score
Stocks, Bonds, Options, ETFs, Futures, Money market funds
$0
$0
3.60%
Deposit or transfer $100,000+ to earn a 4% Match Bonus, or $2,000+ to earn a 3% Match Bonus. Plus: Get a $100 transfer fee reimbursement on your first brokerage transfer of $2,000 or more. T&Cs apply.
Trade stocks, ETFs and equity options commission-free, with access to futures, advanced charting tools, a robo-advisor and event trading powered by Kalshi.
Interactive Brokers logo
Finder score
Finder score
Stocks, Options, Mutual funds, ETFs, Cryptocurrency
$0
$0
3.83% Lite
4.83% Pro
Trade in a simulated trading environment and access a wide range of tradable assets.
eToro logo
Finder score
Finder score
Stocks, Options, ETFs, Cryptocurrency, Investments
$0
$0
3.75%
No commission stock, ETF and options trades, with 3.9% interest on your options account balance and no options contract fees. See full disclosure.
Acorns logo
Finder score
Finder score
Stocks, ETFs
$0
$0
N/A
Get a $20 bonus when you set up an account and make your first recurring investment (min. $5). T&Cs apply.
Automate investing with recurring contributions starting at $5 and invest spare change from everyday purchases.
Stash Investments LLC logo
Finder score
Finder score
Stocks, ETFs
$0
$0
0.1%
Get $5 when you sign up and deposit $5. T&Cs apply.
Bank, automate your portfolio or invest in individual stocks and ETFs for as low as $3 per month.
Wealthfront logo
Finder score
Finder score
Stocks, ETFs, High-yield cash account
$0
$500
3.75%
Get a $50 bonus when you sign up and fund a taxable automated investing account with at least $500. T&Cs apply.
Automate your stock and bond portfolio or trade individual stocks for as little as $1 apiece. Plus, earn 3.50% APY on your cash.
JPMorgan logo
Finder score
Finder score
Mutual funds, ETFs
$0
$25,000
N/A
Financial planning, advice and portfolio management. T&Cs apply.
Get ongoing access to an advisory team with personalized financial planning and expert-built portfolios. Provider terms & conditions apply
M1 Finance logo
Finder score
Finder score
Stocks, ETFs, Cryptocurrency
$0
$100
4.00%
Build a custom portfolio of stocks and ETFs with automatic rebalancing. Plus, earn 4.00% APY with a high-yield cash account.
loading
Showing 12 of 12 results

What is the Finder Score?

The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.

We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.

Read the full Finder Score breakdown

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Monte Rosa Therapeutics stock price (NASDAQ: GLUE)

Use our graph to track the performance of GLUE stocks over time.

Monte Rosa Therapeutics shares at a glance

Information last updated 2025-12-01.
52-week range$3.50 - $16.66
50-day moving average $11.01
200-day moving average $6.53
Wall St. target price$17.20
PE ratio 50.5313
Dividend yield N/A
Earnings per share (TTM) $0.32

Is it a good time to buy Monte Rosa Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monte Rosa Therapeutics price performance over time

Historical closes compared with the close of $15.41 from 2025-12-02

1 week (2025-11-28) -4.70%
1 month (2025-11-05) 25.18%
3 months (2025-09-05) 211.94%
6 months (2025-06-05) 233.55%
1 year (2024-12-05) 74.52%
2 years (2023-12-05) 405.25%
3 years (2022-12-05) 63.41%
5 years (2020-12-01) N/A

Is Monte Rosa Therapeutics stock undervalued or overvalued?

Valuing Monte Rosa Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Monte Rosa Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Monte Rosa Therapeutics's P/E ratio

Monte Rosa Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 51x. In other words, Monte Rosa Therapeutics shares trade at around 51x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

However, Monte Rosa Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

Monte Rosa Therapeutics's EBITDA

Monte Rosa Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $16.8 million.

The EBITDA is a measure of a Monte Rosa Therapeutics's overall financial performance and is widely used to measure a its profitability.

To put Monte Rosa Therapeutics's EBITDA into context you can compare it against that of similar companies.

Monte Rosa Therapeutics financials

Revenue TTM $181.5 million
Gross profit TTM $51 million
Return on assets TTM 1.37%
Return on equity TTM 9.28%
Profit margin 11.54%
Book value $3.98
Market Capitalization $1.1 billion

TTM: trailing 12 months

Monte Rosa Therapeutics share dividends

We're not expecting Monte Rosa Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Monte Rosa Therapeutics share price volatility

Over the last 12 months, Monte Rosa Therapeutics's shares have ranged in value from as little as $3.5001 up to $16.66. A popular way to gauge a stock's volatility is its "beta".

GLUE.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Monte Rosa Therapeutics's is 1.62. This would suggest that Monte Rosa Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

To put Monte Rosa Therapeutics's beta into context you can compare it against those of similar companies.

Monte Rosa Therapeutics overview

Monte Rosa Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1b and the NLRP3 inflammasome. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F.

Frequently asked questions

What percentage of Monte Rosa Therapeutics is owned by insiders or institutions?
Currently 0.69% of Monte Rosa Therapeutics shares are held by insiders and 105.556% by institutions.
How many people work for Monte Rosa Therapeutics?
Latest data suggests 147 work at Monte Rosa Therapeutics.
When does the fiscal year end for Monte Rosa Therapeutics?
Monte Rosa Therapeutics's fiscal year ends in December.
Where is Monte Rosa Therapeutics based?
Monte Rosa Therapeutics's address is: 321 Harrison Avenue, Boston, MA, United States, 02118
What is Monte Rosa Therapeutics's ISIN number?
Monte Rosa Therapeutics's international securities identification number is: US61225M1027
What is Monte Rosa Therapeutics's CUSIP number?
Monte Rosa Therapeutics's Committee on Uniform Securities Identification Procedures number is: 61225M102

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

More guides on Finder

Go to site